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The term “personalized medicine” increasingly has come to mean the use
of genetic testing in prescribing pharmaceutical products.1 The scientific
basis of this approach to medicine is
that, because of genetic variations,
humans differ in their response to
treatments. This observation is the
cornerstone of pharmacogenetics and
pharmacogenomics.
Ethical problems sometimes arise
when this principle is applied on a
group basis. For example, if humans
could be divided into two genetic
groups, a group with genotype A and
a group with genotype B, members of
each group might respond differently
to a particular drug. The group with
genotype A might have an adverse
reaction to a drug. The group with
genotype B might have a therapeutic
response to the drug. Personalized
medicine focuses on ensuring that individuals likely to respond positively
to a drug receive it, and individuals
likely to respond negatively are not
given the drug. Although often defined as a way of individually tailoring treatments, personalized medicine is better characterized as a way
of tailoring treatments to groups of
people with some shared genetic trait
or traits. Hence, personalized medicine may be viewed as “subgroup
medicine.”
A key question of subgroup medicine is to ask how should human subgroups be defined. The method of
defining subgroups determines who
is most likely to be tested for a genetic
trait and therefore who receives or
does not receive certain treatments.
For example, if subgroups are defined
based on height, a scientist might determine that people over six feet tall
are more likely to have a certain allele, and that this allele determines

the response to a drug for a particular
disorder. Thus, people over six feet
tall would be more likely to receive a
genetic test, and clinicians would use
the test result to determine whether
they should receive a particular drug.
The result would be an increase in the
“personalized”care for people over six
feet tall. On the other hand, people
under six feet tall with the same disease would not receive the genetic test
and the opportunity for personalized
medicine.
In a world of unlimited resources,
everyone who needed a drug with
pharmacogenetic information associated with it would receive the appropriate genetic test prior to being prescribed this drug. However, genetic
testing of all people who might benefit from a drug raises cost concerns.
In addition, recognition of phenotypic homogeneity (such as similar
blood pressure measurements) often
precedes scientific identification of
the genetic basis of disease. Consequently, researchers often attempt to
determine which subgroups of people
are most likely to have certain known
or presumed alleles. In the absence
of genotypic information, subgroups
may be defined based on a person’s
physical or social environment, disease type, symptoms, and so on. The
focus of this article is the use of ancestry for defining subgroups. Recently,
ancestry has been used to identify
a subgroup of people most likely to
have a certain allele linked to an adverse drug response, and the FDA’s
policy response to this scientific information raises serious concerns.
Overview of Unique
Carbamazepine Labeling
On December 12, 2007, an FDA Alert
was issued that modified the drug
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labeling for the anti-seizure medication carbamazepine by including
genotype and ancestry as factors to
consider when prescribing the drug.2
The alert stated that potentially fatal
skin reactions, Stevens Johnson Syndrome and Toxic Epidermal Necrolysis (SJS/TEN), can be caused by
carbamazepine therapy. SJS/TEN
results in blisters that can be permanently disabling or lethal. The FDA
Alert indicates that patients with
the genetic marker HLA-B*1502 are
more likely to have this reaction when
taking carbamazepine.3 If the label
simply made these statements, phy-

The FDA Alert also indicates that 1015% of people from China, Thailand,
Malaysia, Indonesia, the Phillipines,
and Taiwan carry this gene variant,
but no supporting research studies
are provided.6 Also, the FDA Alert
indicates that about 2–4% of South
Asians and less than 1% of people in
Japan in Korea have this allele, but no
supporting research studies are provided for these statements either.7
The referenced studies used different approaches to determine ancestry (also labeled as “ethnicity” in one
study) including: skin color, place of
birth, and place of birth of the per-

Recently, ancestry has been used to identify a
subgroup of people most likely to have a certain
allele linked to an adverse drug response, and the
FDA’s policy response to this scientific information
raises serious concerns.
sicians prescribing carbamazepine
would have to question whether an
individual had this particular allele
before prescribing the drug. This new
information might lead physicians to
order genetic testing for all patients
prior to prescribing carbamazepine.
Alternatively, they might decide to
choose a different drug with similar
therapeutic properties as carbamazepine without the need for genetic testing. However, the FDA Alert does not
end with these statements. Instead,
another layer of complexity is added
to the algorithm used for prescribing
carbamazepine.
The FDA Alert indicates that the
genetic variant HLA-B*1502 occurs
“almost exclusively” in patients with
ancestry across “broad areas of Asia,
including South Asian Indians.”4 This
statement is based on a number of
studies performed in patients labeled
as Caucasian, French, German, ethnic Han Chinese residing in Taiwan
or Hong Kong, and Chinese descendants.5 The studies also include three
patients born in Vietnam, Cambodia,
and Reunion Island, respectively, who
were thought to have Asian ancestry.
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son’s parents. In two of the studies,
no clear method of determining ancestry was discussed. Contrary to the
FDA Alert, these individuals were not
from broad areas of Asia, but instead,
a select group of Asian countries. In
some cases, only one individual represented the population of the country,
which is clearly insufficient to draw a
conclusion about the frequency of the
allele in that population. Further, the
FDA Alert is not specific about the
definition of Asia. In fact, a modern
map of Asia includes a much larger
region than these studies cover.8 A
number of countries are not included
in these studies, such as Russia, which
makes up nearly half of Asia, Mongolia, Turkey, Saudi Arabia, and more.
Hence, the statement that people
from broad areas of Asia have this allele seems to lack support.
The FDA Alert also indicates that
the allele is “largely absent in individuals not of Asian origin.” However,
no studies are provided which assess
the prevalence of this allele in other
populations, except individuals labeled as Caucasian, French, and German. For example, no African popu-

lation studies are referenced. A more
thoughtful alert would have recognized the limitations of these studies
and stated that the prevalence of the
allele in other populations of various
ancestral backgrounds has yet to be
determined.
The FDA Alert also states that
patients with ancestry from areas in
which the allele is present (presumably “broad areas of Asia”) should
be screened before starting treatment. With these statements the
FDA creates a new standard of care
for physicians. Given this information, a physician must decide first if
a patient needs carbamazepine, then
determine if the patient is of Asian
ancestry in calculating the risk of an
adverse reaction and the need for a
genetic test. It is unclear how the
physician is to determine whether a
patient has ancestry from broad areas
of Asia. This problem arises whenever ancestry or other social categories are used in stratifying patients for
subgroup medicine.
To date, biomedical researchers
and physicians do not have a widely
used test to determine if a person is of
Asian ancestry or has ancestry from
any other region. As a result, both researchers and physicians can only ask
a patient and hope that the patient
is right. With an increasingly mobile
and admixed population, patients’
assumptions about their ancestry
might not always be correct. The
FDA’s new approach to drug labeling
thus increases the responsibilities of
patients, and with potentially serious
consequences.
The FDA Alert further states that if
an individual tests positive for the allele that he or she should not receive
carbamazepine unless the “benefit
clearly outweighs the risk of serious
skin reactions.”9 The FDA provides no
guidance on how to weigh these risks
and benefits. In addition, the alert
states that patients who have taken
carbamazepine for a few months
without having skin reactions are at
low risk of these events taking place.
Ninety percent of people are thought
to react within the first few months,
with 10% having reactions at a later
point.10 The alert states that this low
risk exists even for individuals who
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are positive for the genetic marker
and for patients of all ethnicities or
genotypes, thereby contradicting,
to some degree, the focus on people
of Asian ancestry. The alert also
states that SJS/TEN can occur even
in people outside of the high-risk
groups, so physicians should watch
for symptoms regardless of whether
a patient has the HLA-B*1502 allele.
This statement seems to acknowledge
the confusion caused by the focus on
ancestry and provides a way for the
FDA to recognize that risks exist for
anyone taking the drug. Finally, the
alert indicates that all of this information will be included in updated drug
labeling for carbamazepine. Overall,
the alert provides unacceptably vague
and confusing guidance for physicians seeking to utilize this information to improve patient care and informing patients.

government-financed health care, including Medicaid and Medicare, are
likely to have greater cost concerns
when considering genetic testing for
which there is usually no reimbursement. Also, the question could arise
as to whether these public programs
would be engaging in race or national
origin discrimination if they do not
pay for genetic testing. Similarly, if
private insurers do not pay for this
test, they could be viewed as also discriminating against a socially defined
group of individuals.
On the other hand, payers might
conclude that it is cost-effective to
pay for genetic testing for people who
are at high risk in order to save money
that would be spent treating patients
with SJS/TEN. The availability of
this test, especially for patients receiving public insurance, would likely
be based on whether the prevention

Conclusion
The FDA’s use of ancestry in labeling carbamazepine is analogous to
the FDA’s racially limited approval of
the drug BiDil, which was labeled as
being for African Americans only.11
The BiDil approval turned out to be
scientifically, ethically, and commercially problematic.12 BiDil and carbamazepine demonstrate the need
for a better approach than stratifying people based on self-identified
or “researcher identified” ethnicity or
ancestry.
The use of ancestry to stratify populations is appealing because it is easier and less costly than genotyping.
Yet, such an approach requires two
key factors: (1) a scientifically valid
way of ascertaining ancestry, and (2)
there must be definitive evidence of
an association between a particular
genotype and a certain ancestry. Over

The use of ancestry in the drug labeling creates potential safety problems for
patients, cost concerns for patients and insurers, and potential stigmatization
of a drug that has been used for years to treat complex neurological illnesses.
Categorizing people for personalized medicine must be done, if at all, in a
scientifically valid, sensitive, and ethical manner.
Cost Concerns
Because of the focus on people of
Asian ancestry, the cost of care may
increase for one subgroup of individuals but not others. Depending on
the cost of genetic testing, individuals
who are believed to have Asian ancestry will pay more to receive carbamazepine than individuals who do not
think they have Asian ancestry. This
increased cost for a particular group
may lead to a number of problems.
The test may be viewed as a method
of making these patients pay more for
their care, and thereby discriminating
against the group. Such cost concerns
could lead to disparities in who receives this drug – with people of Asian
ancestry less likely to receive the drug
in order to avoid the costs. These cost
concerns may seem more daunting
depending on whether insurers approve payment for the genetic test.
In particular, individuals who receive

of harm cost less than dealing with
the harm of SJS/TEN. Because SJS/
TEN can be fatal, the benefits of prevention may be greater for those individuals most at risk. Thus, insurance
companies would need to decide if genetic testing should be approved only
for certain subgroups, because of the
FDA labeling, or if testing should be
approved for all people who need carbamazepine. These problems spring
from the lack of a clear indication of
the role of ancestry in allele frequency
and the lack of a method of determining ancestry. Hence, a more scientific
approach of classifying people with
particular ancestral backgrounds
would be useful for public and private
insurers.
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time, low-cost genetic testing will obviate the need to use ancestry as a
low-cost surrogate for genotype. In
the interim, scientifically defensible
methods and definitions of ancestry
need to be developed.
The inclusion of genetic information in the drug labeling of carbamazepine holds promise for individuals who have the HLA-B*1502 allele,
which is linked to adverse reactions
to this drug. However, the use of ancestry in the drug labeling creates potential safety problems for patients,
cost concerns for patients and insurers, and potential stigmatization of a
drug that has been used for years to
treat complex neurological illnesses.
Categorizing people for personalized
medicine must be done, if at all, in a
scientifically valid, sensitive, and ethical manner.
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